10 , 28 , 88 In addition, we found a positive trend for the use of rituximab in the adjusted multivariate analysis, reinforcing the usefulness of B cell-depleting agents in cryoglobulinemia 22 , 26 together with plasma exchange, as proposed for other systemic vasculitides. 41 In spite of the limited data and the lack of case-control studies, the hig
← all excerpts
Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients.
1
—
—